<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281515</url>
  </required_header>
  <id_info>
    <org_study_id>AGO-OVAR 15</org_study_id>
    <nct_id>NCT00281515</nct_id>
  </id_info>
  <brief_title>Comparison of Paclitaxel/Carboplatin and Lonafarnib to Paclitaxel/Carboplatin for First-line Treatment of Ovarian Cancer</brief_title>
  <official_title>An Open-label, Multicenter, Randomized Phase II Study to Compare the Effects of Paclitaxel/Carboplatin and Lonafarnib to Those of Paclitaxel/Carboplatin for First-line Treatment of Patients With Epithelial Ovarian Cancer FIGO Stages IIB-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGO Study Group</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of Paclitaxel/Carboplatin and Lonafarnib
      to those of Paclitaxel/Carboplatin in primary treatment of patients with epithelial ovarian
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Today the standard therapy for patients with advanced ovarian carcinoma is paclitaxel and
      carboplatin. Lonafarnib is a farnesyl transferase inhibitor (FTI) that is active against a
      broad spectrum of tumor cell lines in vitro and tumor xenografts in nude mice. Lonafarnib has
      single-agent antitumor activity as well as enhanced activity in combination with taxanes in a
      number of tumor cell lines and in vivo models.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>every 3 months until PD</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate (CR/PR (RECIST))</measure>
    <time_frame>During whole trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Until Progression of disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until date of death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety based on nature, frequency and severity of adverse events</measure>
    <time_frame>During treatment phase until resolution</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predose lonafarnib concentrations</measure>
    <time_frame>During treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD activity</measure>
    <time_frame>Assessment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Lonafarnib / Paclitaxel /Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard Chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lonafarnib</intervention_name>
    <description>100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day</description>
    <arm_group_label>Lonafarnib / Paclitaxel /Carboplatin</arm_group_label>
    <arm_group_label>Paclitaxel/Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated patients with a histologically confirmed diagnosis of cancer of
             the ovary, the fallopian tube or extra-ovarian papillary serous tumors FIGO stage
             IIB-IV, regardless of measurable or non-measurable disease

          -  Age &gt;= 18 years

          -  ECOG performance status &lt;= 2

          -  Life-expectancy of at least 6 months

          -  Adequate bone marrow, renal and hepatic function:

        WBC &gt;= 3.0 x 10^9/l; Neutrophils (ANC) &gt;= 1.5 x 10^9/l; Platelets &gt;= 100 x 10^9/l;
        Hemoglobin &gt; 6 mmol/l (&gt; 10.0 g/dl); Bilirubin &lt;= 1 x upper limit of normal range; Alkaline
        phosphatase &lt;= 2.5 x upper limit of normal range; estimated GFR &gt;= 50 ml/min according to
        Jelliffe or Cockroft-Gault formula

          -  Patients who have given their signed and written informed consent to participate in
             the trial after fully understanding the implication and constraints of the protocol

          -  Patients must be geographically accessible for treatment and follow-up

          -  Time between definitive surgery and randomization into the study &lt;= 6 weeks

        Exclusion Criteria:

          -  Ovarian tumors of low malignant potential (borderline tumors)

          -  Non-epithelial ovarian or mixed epithelial/nonepithelial tumors (e.g. Mixed Mullerian
             tumors)

          -  Patients who have received previous chemotherapy or radiotherapy

          -  Prior treatment with FT inhibitors

          -  Patients with a prior diagnosis of any malignancy not cured by surgery alone less than
             5 years before study entry (except in situ carcinoma of the cervix or adequately
             treated basal cell carcinoma of the skin)

          -  Complete bowel obstruction or the presence of symptomatic brain metastases

          -  Concurrent severe medical problems unrelated to malignancy which would significantly
             limit full compliance with the study or expose the patient to extreme risk or
             decreased life expectancy

          -  Patients with a history of seizure disorder or central nervous system disorders;
             pre-existing motor or sensory neurologic pathology or symptoms &gt; NCI grade 1

          -  History of congestive heart failure (NYHA Classification &gt; 2, even if medically
             controlled.

          -  History of clinical and electrocardiographically documented myocardial infarction
             within the last 6 months.

          -  History of atrial or ventricular arrhythmias (&gt;= LOWN II)

          -  Patients with significant Fridericia QTc (QTcF) prolongation at Baseline (ie. QTcF &gt;=
             470 msec)

          -  Patients with severe active infection

          -  Patients with a history of severe hypersensitivity reactions to products containing
             Cremophor EL (cyclosporin or vitamin K) and/or patients with known hypersensitivity to
             compounds chemically related to Carboplatin and Paclitaxel

          -  Women with childbearing potential and who are sexually active and unwilling to use a
             medically acceptable method of contraception (oral contraceptive, diaphragm with
             spermicide, intrauterine device, condom with spermicide)

          -  Women who are pregnant or breast feeding

          -  Administration of other anticancer therapy or simultaneous chemotherapeutic and/or
             hormonal drugs, or radiotherapy during the study treatment period (except: hormonal
             replacement therapy and/or steroid antiemetics)

          -  Patients who are participating in any other clinical study

          -  Dementia or significantly altered mental status that would prohibit the understanding
             and giving of informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Werner Meier, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ev. Krankenhaus, Düsseldorf, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum, Klinik für Frauenheilkunde</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen Mitte, Frauenklinik</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carl-Gustav-Carus der TU Dresden, Universitäts-Frauenklinik</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus, Frauenklinik</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Frauenheilkunde der Univ. Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe Universität, Klinik für Frauenheilkunde u. Geburtshilfe</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg, Frauenklinik</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kreiskrankenhaus, Frauenklinik</name>
      <address>
        <city>Gifhorn</city>
        <zip>38518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik u. Poliklinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Greifswald</city>
        <zip>17487</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincentius-Krankenhäuser</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel, Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Otto-von-Guericke Universität, Frauenklinik</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes-Gutenberg-Universität, Universitäts-Frauenklinik</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Philipps-Universität Marburg, Klinik für Gynäkologie, Gynäkologische Endokrinologie</name>
      <address>
        <city>Marburg</city>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Großhadern, Frauenklinik</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar der TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elblandkliniken, Frauenklinik</name>
      <address>
        <city>Radebeul</city>
        <zip>01445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Südstadt</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäts-Frauenklinik</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsfrauenklinik</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst Schmidt Klinik, Gynäkologie u. Gynäkologische Onkologie</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Meier W, du Bois A, Rau J, Gropp-Meier M, Baumann K, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A, Stähle A, Burges A, Sehouli J. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol. 2012 Aug;126(2):236-40. doi: 10.1016/j.ygyno.2012.04.050. Epub 2012 May 4.</citation>
    <PMID>22564713</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Lonafarnib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

